ProKidney Corp. develops rilparencel, also described as REACT or Renal Autologous Cell Therapy, as an autologous cell therapy candidate for patients with advanced chronic kidney disease and diabetes. News about PROK centers on clinical data from REGEN-007, Phase 3 PROACT 1/REGEN-006 development, regulatory interactions with the FDA on the use of eGFR slope in an accelerated approval pathway, and scientific presentations in nephrology forums.
Company updates also cover quarterly and annual financial results, cash runway commentary, investor conference participation, and leadership additions tied to commercial planning for rilparencel.
ProKidney Corp. (Nasdaq: PROK) announced it will present five posters on chronic kidney disease (CKD) during the ASN Annual Meeting in Orlando, FL, from November 3-6, 2022. Topics include CKD prevalence, gender differences in progression, and the effects of SGLT2 inhibitors. The company will hold an investor briefing on November 3. The lead product candidate, REACT™, aims to slow CKD progression and has received RMAT designation. CKD affects approximately 75 million people in the U.S. and Europe, with significant healthcare costs associated.
ProKidney Corp. (Nasdaq: PROK) announced that CEO Dr. Tim Bertram will present a corporate overview at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 1:30 p.m. ET in New York, NY. Investors can access the live webcast via ProKidney's investor relations website. The company focuses on cellular therapeutics for chronic kidney disease (CKD), particularly their lead product REACT™, which has received RMAT designation and supports ongoing Phase 3 clinical trials. CKD affects approximately 75 million people in the U.S. and Europe, posing significant health risks.
ProKidney Corp. (Nasdaq: PROK) announced that CEO Dr. Tim Bertram will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, in New York, NY. The discussion will cover commercialization strategies, cost reduction, and manufacturing scalability for their lead product REACT™, a novel therapy for chronic kidney disease (CKD). A live webcast will be available on their investor relations site. ProKidney aims to slow CKD progression and improve kidney function through innovative cellular therapies.
ProKidney Corp. (Nasdaq: PROK) has appointed Glenn Schulman as Senior Vice President of Investor Relations, effective immediately. With nearly 20 years of experience in investor relations and corporate communications, Schulman aims to enhance ProKidney's visibility and shareholder value as it advances its lead product, REACT™, through clinical development. REACT™ is a patented cellular therapy for chronic kidney disease, currently in Phase 3 trials. CFO James Coulston expressed confidence in Schulman's expertise to foster long-term success for the company.
ProKidney Corp. (Nasdaq: PROK) reported financial results for Q2 2022 following its business combination with Social Capital Suvretta Holdings. The company secured $596.5 million in gross proceeds to support its Phase 3 program for REACT™, aimed at treating chronic kidney disease (CKD). As of June 30, 2022, ProKidney's cash and equivalents were $21.9 million, up from $20.6 million at the end of 2021. R&D expenses rose to $11.6 million, while G&A expenses surged to $9.2 million. The diluted net loss per share stood at $(0.12), compared to $(0.09) in Q2 2021.
ProKidney Corp. (Nasdaq: PROK) announces the addition of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors, enhancing its leadership team. Maraganore, with over 35 years of experience, previously founded Alnylam Pharmaceuticals and is an advisor at several investment funds. Fox brings over 25 years of healthcare investment banking experience, previously associated with Nuvation Bio and CitiGroup. Both appointees will support ProKidney’s mission to advance its REACT™ therapy for chronic kidney disease during a critical development phase.
ProKidney Corp. (Nasdaq: PROK) has appointed Dr. Kerry Cooper as Senior Vice President of Medical Affairs, enhancing its leadership in treating Chronic Kidney Disease (CKD). Dr. Cooper, previously with AstraZeneca, brings nearly 40 years of clinical and industry experience, having led nephrology programs and established strong ties within the kidney advocacy community. His expertise will be crucial as ProKidney advances its candidate REACT™, a novel therapy aimed at reversing CKD's progression. This appointment comes as ProKidney prepares for further clinical studies.
ProKidney Corp., focused on chronic kidney disease (CKD), commenced trading on Nasdaq as "PROK" on July 12, 2022, following a merger with Social Capital Suvretta Holdings Corp. III. The company raised approximately $597 million in gross proceeds, primarily to fund ongoing Phase 2 and 3 clinical trials for its lead therapy, REACT™. This innovative cell therapy aims to improve kidney function in late-stage CKD patients. The firm is guided by an experienced management team and has filed over 200 patents, underscoring its commitment to advancing CKD treatments.